SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-20-165216
Filing Date
2020-06-10
Accepted
2020-06-10 09:29:34
Documents
5
Period of Report
2020-06-08
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d942082d8k.htm 8-K 24864
2 EX-1.1 d942082dex11.htm EX-1.1 249841
3 EX-5.1 d942082dex51.htm EX-5.1 11961
4 EX-99.1 d942082dex991.htm EX-99.1 8407
5 GRAPHIC g942082g0610011322612.jpg GRAPHIC 2533
  Complete submission text file 0001193125-20-165216.txt   299892
Mailing Address 4000 SHORELINE COURT, SUITE 300 SOUTH SAN FRANCISCO CA 94080
Business Address 4000 SHORELINE COURT, SUITE 300 SOUTH SAN FRANCISCO CA 94080 650-822-5600
Kezar Life Sciences, Inc. (Filer) CIK: 0001645666 (see all company filings)

IRS No.: 473366145 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38542 | Film No.: 20953656
SIC: 2834 Pharmaceutical Preparations